Abstract

Introduction

Schizophrenia is a chronic illness associated with periods of relapse and remission and poor long-term outcomes.¹ The period surrounding the first episode of psychosis represents a critical juncture in the natural course of the disease, particularly in young patients for whom symptoms and impaired functioning may be less well established.^2,3 Untreated psychosis may have untoward effects on neurobiologic function, and lack of intervention in first-episode psychosis (FEP) or early schizophrenia may lead to prolonged times to remission later in the course of the disease, as well as reduced recovery and potential treatment resistance.² At least 50% of patients with schizophrenia receiving either intermittent or continuous antipsychotic treatment experience occasions of unremitting hallucinations, delusions, disorganized thinking, and negative symptoms >10 years after disease onset, and this can disrupt the development of interpersonal and occupational skills.^2,4

A recently published systematic review and meta-analysis demonstrated that a long duration of untreated psychosis has small but statistically significant correlations with poor overall symptomatic outcome as well as more severe positive and negative symptoms, failure to achieve remission, impaired social functioning, and decreased global outcome (eg, combined clinical/social outcome or outcome on Global Assessment of Functioning scale).⁵ These results suggest that intervention in FEP or early schizophrenia may benefit long-term outcomes.

A number of recent systematic reviews and meta-analyses have evaluated the efficacy of antipsychotics in relapse prevention and in FEP or early schizophrenia.^6–10 However, none have addressed the long-term impact of intervention in FEP or early schizophrenia on the key outcomes of remission, relapse, or cognition. Ventura et al¹¹ demonstrated that the Wechsler Adult Intelligence Scale comprehension score, a measure of cognition, was a good predictor of functional outcome at 6 months following FEP in schizophrenia. This is consistent with prior studies associating cognition with functional outcome.^12–14 We chose to focus on cognition because it is a pervasive aspect of schizophrenia; cognitive deficits may contribute to poor functional and social outcomes and diminished quality of life.¹⁵ Cognitive impairment may worsen with disease duration but may be amenable to long-term improvement accompanying control of psychopathology. Thus, it was of interest to assess whether evidence was available showing that starting antipsychotic treatment early in the disease course could improve or stabilize cognitive functioning. The objective of this systematic review was to evaluate the effect of treatment with oral and long-acting injectable (LAI) antipsychotics on long-term outcomes in patients with FEP or early schizophrenia. For comparing and contrasting the differences when treatment is started later in the course of the disease, studies assessing long-term outcomes when treating patients with a longer disease history were also examined.

Materials and methods

Results

Search results: study characteristics

Study identification, screening, and eligibility are summarized in Figure 1. Database searching yielded 785 unique references; 511 references were excluded after title screening and 179 were excluded after abstract screening. The remaining 95 articles were subjected to full-text review, during which another seven potential articles were identified and subsequently reviewed for inclusion. Of the 102 articles reviewed in full, 83 were excluded, leaving 19 articles: 13 included analysis of long-term outcomes of remission or relapse^16–20 (Table 1) or cognition^21–27 (Table 2) in patients with FEP and six reported on patients with a longer disease history^28–33 (Table 3).

Open in a separate window

Figure 1

Flow diagram of article selection.

Note: ^aAdditional full-text articles (n=7) were identified from the references cited in studies that met inclusion/exclusion criteria and were also assessed for eligibility.

Abbreviation: HEOR, health economics and outcomes research.

Table 1

Remission and relapse in long-term treatment studies of FEP

References	N	Patient populationa	Study design	Follow-up	End point	Results
Lieberman et al18	(1 year) 160	FEP, treatment naïve or received antipsychotic treatment for <2 weeks	R, DB, 1-year comparison of treatment with clozapine and chlorpromazine	1 year	Remission	Clozapine, 81%; chlorpromazine, 79%
Emsley et al17	50	FEP, duration ≤1 year	Single-arm, open-label, risperidone LAI	2 years	Remission	64% at any time during the study, 62% maintained throughout the 2-year study
Chen et al16	178	FEP, remitted after >1 year of antipsychotic treatment	R, DB comparison of maintenance therapy with quetiapine or discontinuation (placebo)	1 year or until relapse	Risk of relapseb	Quetiapine, 41%; placebo, 79% (P<0.001)
Schooler et al19	555	FEP, duration ≤1 year	R, DB comparison of treatment with risperidone and haloperidol	192 days and 218 days, respectively (median); 1,514 days (max)	Relapse rates	Risperidone, 42%; haloperidol, 55% Time from response to relapse: 466 days (risperidone) vs 205 days (haloperidol) (P=0.008)
Wunderink et al20	(18 months) 131	FEP in remission for 6 months	R, OL comparison of maintenance therapy or guided discontinuation	18 months	Relapse rates	Maintenance therapy, 21%; guided discontinuation, 43% (HR, 2.3; P=0.011)

Open in a separate window

Notes:

^aPatients had schizophrenia, schizoaffective disorder, or schizophreniform disorders.

^bUnivariate Cox proportional hazards model was used to analyze potential predictors of relapse. Relative risk was calculated as the ratio between the outcome (relapse) rate in the population exposed to the risk factor (placebo) divided by the outcome rate in the population not exposed to the risk factor (maintenance quetiapine).

Abbreviations: DB, double blind; FEP, first-episode psychosis; HR, hazard ratio; OL, open-label; LAI, long-acting injectable; R, randomized.

Table 2

Cognitive improvement in long-term treatment studies of FEP

References	N	Patient populationa	Study design	Follow-up	End point	Results
Cuesta et al22	100	FEP, treatment naïve	R, comparison of olanzapine and risperidone, naturalistic	6 months	Global score based on 14 cognitive measures	No difference between groups Significant improvement at 6 months in 30% of the patients
Davidson et al23	286	FEP, antipsychotic exposure <2 weeks in prior year or <6 weeks lifetime	R, OL comparison of haloperidol, amisulpride, olanzapine, quetiapine, and ziprasidone	6 months	Composite of five neurocognitive tests	Moderate improvement in all treatment groups (NS) Lower baseline scores predicted greater improvement at 6 months
Crespo-Facorro et al21	104	FEP, treatment naïve or antipsychotic treatment <6 weeks	R, OL comparison of olanzapine, risperidone, and haloperidol	1 year	Cognitive improvement at 1 year	All drugs equally improved cognitive deficits (NS)
Keefe et al25	400	FEP, 24.1% antipsychotic naïve	R, DB comparison of olanzapine, quetiapine, and risperidone	1 year	Composite score from the CATIE neurocognitive battery	No difference among groups Significant improvement in each group at 12 weeks; no additional improvement at 52 weeks
Olivier et al26	92 cases 100 controls	FEP, antipsychotic exposure ≤4 weeks, no previous LAIs 60% cases antipsychotic naïve	Case-control, longitudinal, single-arm, and flupenthixol LAI	1 year	Composite score of cognitive tests	Significantly greater improvement at 6 months and 12 months among cases compared with healthy controls
Purdon et al27	65	Early-phase schizophrenia (ie, ≤5 years since first exposure to neuroleptic treatment), mild symptom severity, and clinically stable at baseline	R, DB comparison of olanzapine, risperidone, and haloperidol	54 weeks	General cognitive index computed from the mean of six domains of cognitive function	Within groups: significant improvement from baseline at 54 weeks with olanzapine and risperidone, but no improvement with haloperidol (risperidone was no longer significant in the completed analysis) Between groups: olanzapine superior to haloperidol and risperidone; no difference between haloperidol and risperidone
Keefe et al24	1 year: 58 2 years: 26	FEP	R, DB comparison of olanzapine and low-dose haloperidol	2 years	Weighted composite of eight (1 year) and two (2 years) neurocognitive tests	Cognitive scores improved in both groups at years 1 and 2 (NS)

Open in a separate window

Note:

^aPatients had schizophrenia, schizoaffective disorder, or schizophreniform disorders.

Abbreviations: CATIE, Clinical Antipsychotic Trials of Intervention Effectiveness; DB, double blind; FEP, first-episode psychosis; LAI, long-acting injectable; NS, not statistically significant difference between groups; OL, open-label; R, randomized.

Table 3

Relapse and cognitive improvement in studies of patients with longer disease history

References	N	Patient populationa	Study design	Follow-up	End point	Results
Csernansky et al28	397	Clinically stable with inpatient psychiatric hospitalization, daytime psychiatric hospitalization, outpatient crisis management, or short term treatment in a psychiatric hospital ER ≤24 months before study entry	R, DB comparison of treatment with risperidone or haloperidol	Risperidone, 364 days (median); haloperidol, 238 days (median)	Risk of relapse	Risperidone, 34%; haloperidol, 60% (P<0.001)
Gaebel et al29	710	Symptomatically stable	R, OL comparison of treatment with risperidone LAI and quetiapine	2 years	Time to relapse	Longer time to relapse with risperidone LAI (P<0.0001); 25th quartile, 248 days for quetiapine; not reached for risperidone LAI
Kasper et al30	1,294	Chronic, currently experiencing an acute relapse	R, DB comparison of treatment with aripiprazole and haloperidol	52 weeks	Time to relapse in responders	Comparable time to relapse in responders with aripiprazole and haloperidol (77% and 73%, respectively; risk ratio, 0.88, P=0.427)
Pigott et al31	310	Chronic (≥2 years since diagnosis) and stable	R, DB comparison of treatment with aripiprazole and placebo	26 weeks	Time to relapse (Kaplan–Meier estimate), relapse rate	Significantly longer time to relapse with aripiprazole compared with placebo (median time to relapse and 95% CIs were not estimable because <50% of patients relapsed in the aripiprazole treatment group); the estimated Kaplan–Meier survival rates at week 26 were significantly higher with aripiprazole (62.6%) compared with placebo (39.4%, P<0.001; RR, 0.50, 95% CI, 0.35–0.71)
Ruhrmann et al32	153	Chronic (duration ≥2 years), stable, with predominantly negative symptoms	R, DB, comparison of treatment with flupentixol and risperidone	≤25 weeks	Relapse rates	Flupentixol, 18.1%; risperidone, 13.9% (NS)
Takeuchi et al33	61	In remission with respect to positive symptoms and treated with stable doses of olanzapine or risperidone	R, open label, comparison of dose reduction (50%) with regular dose (olanzapine or risperidone)	28 weeks	Cognitive function assessed with RBANS total score	Significantly greater improvement at 28 weeks in dose-reduction group vs regular dose

Open in a separate window

Note:

^aPatients had schizophrenia or schizoaffective disorder.

Abbreviations: CI, confidence interval; DB, double blind; ER, emergency room; LAI, long-acting injectable; OL, open-label; R, randomized; NS, not statistically significant; RBANS, Repeatable Battery for the Assessment of Neuropsychological Status; RR, relative risk.

Among the studies including patients defined as having FEP, the patient populations varied broadly with respect to disease duration and prior antipsychotic exposure. Disease duration ranged from 1 month to 5 years. One study did not report disease duration or did not include adequate data to determine the disease duration.¹⁶ Duration of prior antipsychotic exposure ranged from none (treatment naïve) to a median of 21 months; when excluding the study of patients with remitted FEP,¹⁶ the maximum duration of exposure was ≤16 weeks. There were two studies that did not report duration of prior antipsychotic exposure,^17,20 however, in one of the studies, the authors noted that 54% of the patients were treatment naïve at baseline.¹⁷ Of note, in one study, patients were not required to have FEP but had to be in the early phase of schizophrenia, defined as ≤5 years since their first exposure to neuroleptic treatment; the mean disease duration ranged from 2.45 years to 2.79 years among treatment groups.²⁷ This particular study was included in the analysis of early schizophrenia because the authors specifically identified the patients as “in the early phase of schizophrenia,” although it is possible that the patient population overlapped with those in the comparative, later phase studies.

For comparative purposes, there were six studies of patients with schizophrenia or schizoaffective disorder and a longer disease history that met the inclusion criteria (Table 3).^28–33 Disease durations ranged from 10 years to 17 years.^{28–30,32,33} One study did not report disease duration and did not include adequate data to determine the disease duration; however, patients were required to have diagnoses of schizophrenia ≥2 years prior to study entry as part of the study’s inclusion criteria.³¹ Most of the studies in patients with longer disease history included clinically stable patients with residual symptoms;^{28,29,31–33} one study included patients who were currently experiencing a relapse.³⁰ Relapse (risk, time to, or rate of) was reported as a primary outcome in five studies;^28–32 and cognitive function was reported as a primary outcome in one study.³³ Definitions of relapse were based on criteria that included psychiatric hospitalization, increased level of psychiatric care, predefined absolute or percentage increase on the Positive and Negative Syndrome Scale (PANSS) total score, predefined increases on individual PANSS items, predefined decreases on the Brief Psychiatric Rating Scale (BPRS), Clinical Global Impression (CGI) – Improvement score of ≥5 (minimally worse), deliberate self-injury, clinically significant suicidal or homicidal ideation, violent behavior (ie, injuring someone or significant property damage), or an adverse event of worsening schizophrenia.

Remission and relapse

Remission as an outcome was examined in two FEP studies that met the inclusion criteria for this review (Table 1): a randomized, double-blind study that evaluated the onset and duration of remission in 160 treatment naïve patients with FEP after 1 year of treatment with clozapine or chlorpromazine¹⁸ and a single-arm, 2-year, open-label study that evaluated remission, time to remission, and maintenance of remission in 50 patients (54% treatment naïve) treated with risperidone LAI.¹⁷ Patients in the double-blind study¹⁸ had scored ≥4 (moderate severity) on one or more of the five psychosis items on the BPRS at the time of screening. The primary end point, time to first remission, was defined as meeting the following criteria: ≥50% reduction from baseline in the BPRS total score, no score >3 (mild) on the five BPRS psychosis items, and a CGI-severity score ≤3 (mildly ill); in this study, remission did not require that these criteria be met for a specified minimal duration. A high degree of treatment responsiveness was reported for both drugs at study end point, with no differences in the rates of achieving remission before discontinuing or completing the 52-week study (clozapine, 81%; chlorpromazine, 79%). However, time to remission was more rapid (hazard ratio [HR], 1.69; 95% confidence interval [CI], 1.18–2.44; P=0.005) and time spent in remission was longer (odds ratio [OR], 1.73; 95% CI, 1.20–2.50; P=0.003) with clozapine compared with chlorpromazine treatment. The median time to first remission was 8 weeks with clozapine versus 12 weeks with chlorpromazine, χ²(1) =5.56, P=0.02. Logistic regression modeling demonstrated that for every year of untreated psychosis, the odds of achieving remission decreased by 15% (OR, 0.85; 95% CI, 0.75–0.95; P=0.006).¹⁸ The open-label risperidone LAI study used the Remission in Schizophrenia Working Group criteria of remission that require maintaining mild or lower levels (≤3) on eight key PANSS items for ≥6 months.¹⁷ The median time to remission was 301 days; 64% of patients achieved remission during the study and 62% maintained remission throughout the study.

Data on relapse prevention in patients with FEP were also scarce. Three articles evaluating relapse met the inclusion criteria for this review: two studies examined relapse rates and one study evaluated the risk of relapse and relapse rate (Table 1).^16,19,20 Definitions of relapse were based on the criteria that included meeting predefined scores on PANSS items;²⁰ meeting predefined scores on PANSS items and CGI-severity and improvement scores;¹⁶ or meeting predefined increases on PANSS total scores, CGI changes of “much worse” or “very much worse,” and adverse events of deliberate self-injury, clinically significant suicidal or homicidal ideation, or violent behavior (ie, injuring someone or significant property damage).¹⁹

The time course of relapse was examined in a study of 555 patients with FEP who were randomized to receive treatment with haloperidol or risperidone and were followed for up to 4 years.¹⁹ In this cohort, the median time to relapse was 205 days in patients treated with haloperidol and 466 days in patients treated with risperidone (P=0.008); the overall relapse rates were 55% and 42%, respectively, in 400 of the patients who initially achieved clinical improvement.

Maintenance treatment in patients with FEP has also been compared with planned discontinuation. Maintenance treatment with antipsychotic agents for up to 1 year prevents relapse in patients with stable, remitted FEP and is more effective than the strategy of treatment discontinuation (Table 1). In the study reported by Chen et al, 178 patients with FEP who had completed ≥1 year of antipsychotic drug treatment with no relapses were randomized to 1 year of maintenance therapy with quetiapine or had a supervised treatment discontinuation (matched placebo).¹⁶ At baseline, patients had no psychotic symptoms for ≥8 weeks and had been treated with antipsychotics for a mean of 618 days. Univariate Cox proportional hazards model was used to analyze the potential predictors of relapse, and relative risk (RR) was calculated as the ratio between the outcome (relapse) rate in the population exposed to the risk factor (placebo) divided by the outcome rate in the population not exposed to the risk factor (maintenance quetiapine). Risk of relapse at 12 months was 41% for patients receiving maintenance therapy (95% CI, 29%–53%) and 79% for patients undergoing treatment discontinuation (95% CI, 68%–90%; P<0.001).

In a study reported by Wunderink et al, 131 stabilized patients with FEP with antipsychotic therapy for 6 months were randomly assigned to receive maintenance therapy or to undergo guided discontinuation (symptom-guided tapering).²⁰ After 18 months follow-up, the relapse rates were 21% for patients receiving maintenance therapy and 43% among patients assigned to guided discontinuation (HR, 2.3; P=0.011).

Five studies met our search criteria for studies that reported relapse and/or remission in patients with chronic schizophrenia: one placebo-controlled trial, three studies comparing second-generation antipsychotic (SGA) and first-generation antipsychotic (FGA), and one study comparing an LAI with an oral SGA (Table 3).^28–32 A 26-week, randomized, controlled trial in patients with chronic (≥2 years), stable (no significant improvement or worsening ≤3 months prior to study entry) schizophrenia reported significantly higher estimated Kaplan–Meier survival rates at week 26 with oral aripiprazole compared with placebo (relapse rate, 62.6% vs 39.4%, respectively; P<0.001; RR, 0.50, 95% CI, 0.35–0.71). The median time to relapse and 95% CIs were not estimable because <50% of patients in the aripiprazole treatment group relapsed.³¹ In one study of patients with chronic schizophrenia (mean age at onset, ~25 years; mean age at study entry, ~37 years) who were experiencing an acute relapse, high and comparable response rates were observed with the SGA aripiprazole (72%) and the FGA haloperidol (69%) (P=0.362).³⁰ The relapse rates were also comparable between the SGA risperidone (13.9%) and FGA flupentixol (18.1%) in a randomized, double-blind study in patients with chronic schizophrenia (mean time since diagnosis, ~11 years) with predominantly negative symptoms.³² In another study, in which patients had a mean illness duration of >10 years, the Kaplan–Meier estimated risk of relapse at 1 year was significantly lower with risperidone (34%) compared with haloperidol (60%) (P<0.001).²⁸ Switching to a second-generation LAI formulation was shown to provide further benefit in a 2-year, randomized clinical trial in patients with a mean (±standard deviation) time since diagnosis of 9.9 (±9.9) to 10.0 (±10.1) years. In that study, the RR of relapse in patients who switched to risperidone LAI was less than half for those who switched to oral quetiapine from other oral antipsychotics (HR, 0.46; 97% CI, 0.32–0.67).²⁹

In summary, two studies reported remission as a primary outcome in patients with FEP: a double-blind, randomized, 1-year trial in which a similar proportion of patients achieved remission but achieved it earlier and sustained it longer with clozapine versus chlorpromazine¹⁸ and an open-label, 2-year, single-arm study with risperidone LAI in which almost two-thirds of patients achieved remission and remained in remission through the end of the study.¹⁷ Another three studies^16,19,20 assessed relapse rate, timing of relapse, or the risk of relapse in patients with FEP. In one of these studies, relapse rates were lower and median time to relapse was longer for risperidone versus haloperidol.¹⁹ In two studies assessing discontinuation versus maintenance treatment in patients in remission after FEP, maintenance treatment halved the risk of relapse versus placebo (discontinuation)¹⁶ and halved relapse rates versus guided discontinuation.²⁰

Discussion

Treatment of early schizophrenia results in favorable long-term outcomes. Treatment with atypical antipsychotics may result in a faster and more sustained remission compared with FGAs.¹⁸ In general, treatment in patients with FEP has a markedly positive effect on the likelihood of remission¹⁸ and risk¹⁶ or rate²⁰ of relapse. Although the effect is associated with both oral and LAI antipsychotics, one study reported a rate of remission sustained for ≥6 months with LAIs that compared favorably relative to that reported in FEP treated with oral antipsychotics.¹⁷ Patients with a longer duration of schizophrenia (ie, chronic schizophrenia) also demonstrated reduced risk of relapse with antipsychotic therapy versus placebo in one study included in our review,³¹ and in another study, a second-generation LAI conferred greater protection from relapse than an oral FGA.²⁹ Regardless, given the reduced likelihood of remission with longer duration of untreated psychosis,¹⁸ earlier intervention may be best for achieving treatment goals over the long term.

Long-term relapse prevention is an important goal of schizophrenia treatment.⁷ Given the chronic course of schizophrenia, the typical early age at onset, and the adverse events associated with antipsychotic treatment,³⁶ it would seem rational to attempt trials of drug discontinuation over the course of the disease. However, the results of two studies of treatment discontinuation or intermittent/guided discontinuation identified in this systematic review demonstrate that uninterrupted maintenance therapy for up to 2 years is a significantly more effective option for preventing relapses in patients with FEP.^16,20 These findings are in concordance with the observation that, in patients with recent-onset schizophrenia who underwent supervised discontinuation of antipsychotic treatment, exacerbation or relapse of schizophrenia occurs in 78% of patients in the first year and 96% of patients by the second year.³⁷ Nonadherence with antipsychotic medication may also contribute to poor long-term outcome in patients with FEP.³⁸ The results from a nationwide cohort study in Finland show poor antipsychotic treatment adherence in FEP and a significantly lower risk of rehospitalization associated with LAI versus oral formulations.³⁸ Early treatment and patient discharge with LAI antipsychotics versus oral formulations may improve outcomes in patients with FEP.

Improvements in cognitive impairment are another key target in the treatment of schizophrenia.³⁶ There is substantial evidence that impaired cognition is present in many patients with FEP.^39–41 Treatment of FEP does confer cognitive benefits, with relatively modest effects observed from 6 months²³ to 2 years.²⁴ Practice effect may account for some of the observed gains. Crespo-Facorro et al reported that most changes in cognitive score were similar to those attributed to practice effects observed in healthy controls, but in some cognitive variables, the performance gains in patients exceeded those in controls.²¹ In a study that included patient-matched healthy volunteers, improvements observed in controls were of a smaller magnitude than those in the patients.²⁶ Cuesta et al, who did not include a control group in the study design, noted that cognitive improvements were observed not only in tests prone to familiarity and procedural learning but also across the spectrum.²² Practice effect cannot be completely excluded from interpretation of neurocognitive tests; however, it is reasonable to conclude that at least part of the reported cognitive improvement is related to the antipsychotic intervention, especially in studies with long elapsed time between testing.²³

Although antipsychotics improve patients’ neurocognitive function, the deficit is still notable compared with healthy controls.^21,24,26 The magnitude of improvement in neurocognitive test performance appears to be greater in antipsychotic naïve patients relative to those exposed to antipsychotics prior to baseline assessment^24,25 and also in patients with more severe baseline cognitive deficits compared with those having less severe dysfunction.^22,23 Patients previously treated with antipsychotics may have a reduced neurocognitive response to further treatment as suggested by results demonstrating that initial cognitive improvements at early time points are not followed by additional gains at later time points.^25,26 Although such a possibility is not addressed by the studies in our review, identifying patients who may develop schizophrenia through genotyping^42,43 or other means⁴⁴ may provide an opportunity to intervene before cognitive deficits become pronounced or irreversible.

How long-term cognitive improvements associated with FGA or SGA antipsychotics may differ between patients with recent-onset schizophrenia and patients with a longer course of disease remains unknown, although there is evidence that cognitive performance of patients with schizophrenia may be negatively affected by high dosing of antipsychotics.⁴⁵ It is noteworthy that cognitive function, processing speed in particular, improved in patients with chronic schizophrenia when their doses of atypical antipsychotics were reduced to the lower limit of currently recommended doses.³³ However, this finding requires confirmation in a larger and longer double-blind study, and its results preclude generalization, especially to FEP, because of the particular characteristics of the study population. The study population comprised clinically stable patients with a long history of the illness and without significant positive symptoms; such patients may be at a relatively low risk of relapse when treated with reduced doses of antipsychotics.

The objective of our systematic review, to determine the impact of early intervention (ie, in FEP or early schizophrenia) on long-term outcomes of remission, relapse, and cognitive functioning, was clearly defined and entailed careful selection of manuscripts that met the objective. However, the meticulous criteria also narrowed our search to a selected number of journal articles that may not represent all studies in patients with FEP and thus may limit the generalizability of our findings. The small number of articles meeting our criteria emphasizes the need for additional rigorous studies designed to assess long-term outcomes in patients with FEP in schizophrenia. We included studies for which the primary outcome was assessed after 6 months, although a longer time frame would likely provide a stronger indication of long-term outcomes. Moreover, within the FEP studies, the specific patient inclusion criteria were highly variable, indicating a lack of uniformity in the terminology that could also affect the generalizability of the conclusions. It should also be noted that, overall, among the studies, there was a high degree of heterogeneity in the patients’ characteristics, and treatment effects may have been influenced by factors such as the disease severity or genetic variation.⁴⁶ To provide context for the results in patients with FEP, we assessed similar studies in patients with chronic symptomatic schizophrenia. It is notable that there were no studies identified in our search that directly compared outcomes in patients with FEP and those with a longer history of symptomatic schizophrenia; such studies would provide the opportunity to draw conclusions about the potential differences between early and later treatments.

Conclusion

Antipsychotic treatment of patients with FEP appears to confer long-term benefit with regard to maintenance of remission, prevention of relapse, and improvement in cognitive deficits. Delaying treatment may reduce the odds of achieving remission. Primary analyses of long-term outcomes with treatment of FEP are needed to inform clinical decision making during this important period in the course of schizophrenia.

Acknowledgments

Footnotes

References